Skip to content

Gilead Sciences, Inc.: income tax expense or benefit

Gilead Sciences income tax expense or benefit: $1.29 billion for the year ending 2025-12-31, up 509.5% on the year. 19 values since 2007 from SEC filings.

All Gilead Sciences, Inc. financial histories

At a glance

Gilead Sciences reported income tax expense or benefit of $1.29 billion for the year ending 2025-12-31, up 509.5% from $211.0 million a year earlier. Across the last five reported years it ranged from $211.0 million (2024-12-31) to $2.08 billion (2021-12-31). That was 4.4% of revenue ($29.4 billion) for the same year.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Exact concept: us-gaap:IncomeTaxExpenseBenefit. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2007-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.

Selected filing history

Income tax expense or benefit in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
2025-01-012025-12-311,286,000,000USD2026-02-2410-K · 0000882095-26-000006 SEC
2024-01-012024-12-31211,000,000USD2026-02-2410-K · 0000882095-26-000006 SEC
2023-01-012023-12-311,247,000,000USD2026-02-2410-K · 0000882095-26-000006 SEC
2022-01-012022-12-311,248,000,000USD2025-02-2810-K · 0000882095-25-000006 SEC
2021-01-012021-12-312,077,000,000USD2024-02-2310-K · 0000882095-24-000007 SEC
2020-01-012020-12-311,580,000,000USD2023-02-2210-K · 0000882095-23-000007 SEC
2019-01-012019-12-31-204,000,000USD2022-02-2310-K · 0000882095-22-000007 SEC
2018-01-012018-12-312,339,000,000USD2021-02-2510-K · 0000882095-21-000008 SEC
2017-01-012017-12-318,885,000,000USD2020-02-2510-K · 0000882095-20-000006 SEC
2016-01-012016-12-313,609,000,000USD2019-02-2610-K · 0000882095-19-000006 SEC
2015-01-012015-12-313,553,000,000USD2018-02-2710-K · 0000882095-18-000008 SEC
2014-01-012014-12-312,797,000,000USD2017-02-2710-K · 0000882095-17-000006 SEC
2013-01-012013-12-311,151,000,000USD2016-02-2410-K · 0000882095-16-000039 SEC
2012-01-012012-12-311,038,000,000USD2015-02-2510-K · 0000882095-15-000008 SEC
2011-01-012011-12-31861,945,000USD2014-02-2510-K · 0000882095-14-000013 SEC
2010-01-012010-12-311,023,799,000USD2013-02-2710-K · 0000882095-13-000015 SEC
2009-01-012009-12-31876,364,000USD2012-02-2310-K · 0001193125-12-075335 SEC
2008-01-012008-12-31702,363,000USD2011-02-2810-K · 0001193125-11-050041 SEC
2007-01-012007-12-31635,355,000USD2010-03-0110-K · 0001193125-10-044753 SEC

Related GILEAD SCIENCES, INC. histories

All 63 Gilead Sciences histories

Inspect the source

Entity
GILEAD SCIENCES, INC. / CIK 0000882095
Captured
SEC response SHA-256
5703fd84d6e3d00697ac60bc3d7ded9306be2a9f36170a342858b8e6417506f0

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000882095.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))